Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Adicet Bio, Inc. (ACET)

Adicet Bio posts September 2026 investor presentation with program timelines

Neutral Impact 2 of 5 other Written later

Adicet Bio posted a September 2026 investor presentation to its website and furnished it as Exhibit 99.1 to a Form 8-K. The deck covers its prula-cel autoimmune program, its ADI-212 solid tumor candidate and its in vivo CAR-T pipeline, and sets out expected clinical and regulatory milestones.

Key points

  • ADI-212 has an IND cleared in the US, with first-patient dosing anticipated in 4Q26 and clinical data expected in 1H27 and 2H27.
  • Prula-cel clinical data cited in the deck has a cut-off date of August 31, 2025 and covers 7 patients (5 LN and 2 SLE) with follow-up of 2-9 months.
  • The filing describes a CRISPR license for ADI-212 gene-editing technology, with CRISPR holding an opt-in right to a 50/50 cost and profit split.

The filing

CompanyAdicet Bio, Inc. (ACET)
Form8-K, current report
Filed with the SECSep 8, 2026, 4:17 PM ET
Accession number0001720580-26-000056

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.